Peanut allergy drug approved
New hope for peanut allergy sufferers as FDA approves drug to reduce, and potentially eliminate, allergic reactions. Shares of Aimmune Therapeutics skyrocketed in extended trading Friday after the U.S. Food and Drug Administration approved the company’s drug that reduces — and potentially eliminates — kids’ allergic reactions to peanuts.
The pharmaceutical company’s stock was up more than 20 percent as parents their children from ages 4 to 17 received hope on the FDA action. The drug, taken orally, arrests any allergic reactions such as anaphylaxis, that occur after exposure to peanuts. Still, the company says that allergy sufferers still must maintain a peanut-free diet and the drug is not intended as an emergency treatment.
Read the whole story at FoxBusiness